How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

26,324 results for

(title:prostate cancer)

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer CUAJ – CUA Best Practice Report Shayegan et al BPR: PSMA PET in prostate cancer 1 © 2021 Canadian Urological Association Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic (...) resonance (MR) in prostate cancer Bobby Shayegan *1 ; Katherine Zukotynski *2 ; François Bénard 3,4 ; Cynthia Ménard 5 ; Golmehr Sistani 6 ; Glenn Bauman 7 ; Patrick Veit-Haibach 8 ; Ur Metser 9 1 Department of Urology, McMaster University, Hamilton, ON, Canada; 2 Departments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada; 3 PET Functional Imaging, BC Cancer, Vancouver, BC, Canada; 4 Department of Radiology, University of British Columbia, Vancouver, BC, Canada; 5 Department

2021 Canadian Urological Association

2. Prostate cancer: NCCP advice for Medical Professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak

Prostate cancer: NCCP advice for Medical Professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak Version: 2 Department: NCCP Radiation Oncology Working Group Update date: 30/06/2020 Code: RO_COVID19_7 Page 1 of 3 NCCP advice for medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) pandemic This document (...) ) - https://www.gov.ie/en/campaigns/c36c85-covid-19- coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy during the COVID-19 pandemic. In general prostate cancers are either low risk and delaying treatment does not impact outcomes or patients

2020 Health Service Executive (Ireland) - Clinical Guidelines

3. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Full Text available with Trip Pro

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures.We performed

2019 Cochrane

4. Prostate cancer: Scenario: Management of complications of prostate cancer and adverse effects of treatments

Prostate cancer: Scenario: Management of complications of prostate cancer and adverse effects of treatments Scenario: Complications and adverse effects | Management | Prostate cancer | CKS | NICE Search CKS… Menu Scenario: Complications and adverse effects Prostate cancer: Scenario: Management of complications of prostate cancer and adverse effects of treatments Last revised in October 2017 Scenario: Management of complications of prostate cancer and adverse effects of treatments How should I (...) follow up and monitor men with prostate cancer? Men with prostate cancer should be followed up in primary care in line with locally agreed protocols. For all men, review and manage: of the disease, including pain, lower urinary tract symptoms, and symptoms of spinal cord compression. Adverse effects from treatment, including and . Adverse effects of androgen withdrawal include change in body shape and weight gain, tiredness, hot flushes, loss of libido, erectile dysfunction, gynaecomastia, and loss

2019 NICE Clinical Knowledge Summaries

5. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

Prostate cancer screening with prostate-specific antigen (PSA) test Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Prostate cancer... Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline CC BY NC Open access (Published 05 September 2018) Cite this as: BMJ 2018;362:k3581 Population Diagnostic (...) pathway for prostate cancer Localised Stage I or II Stage III or IV Advanced Abnormal biopsy and staging No cancer diagnosis Normal biopsy Still possible to have a biopsy and be diagnosed, based on clinical suspicion No Biopsy Biopsy Normal PSA Elevated PSA or Choices considered in this comparison Prostate-specific antigen (PSA) screening No PSA screening Width of lines proportional to approximate numbers of people Subsequent treatment Surgery Radiation Active surveillance With or without hormonal

2018 BMJ Rapid Recommendations

6. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents Overview 4 Who is it for? 4 Recommendations 5

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

8. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Full Text available with Trip Pro

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK 7 Department of Urology and Surgery, Western General Hospital, University of Edinburgh, Edinburgh, UK 8 Academic Urology Unit, University of Sheffield, Sheffield, UK 9 Department of Urology, Addenbrooke’s Hospital, Cambridge, UK 10 Department of Urology, Queen Elizabeth Hospital, Birmingham, UK 11 Department of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK 12 Department of Urology, Cardiff and Vale

2020 NIHR HTA programme

9. Relugolix (Orgovyx) - To treat advanced prostate cancer

Relugolix (Orgovyx) - To treat advanced prostate cancer Drug Approval Package: ORGOVYX U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ORGOVYX Company: Myovant Sciences GmbH Application Number: 214621 Approval Date: 12/18/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

10. Gallium 68 PSMA-11 - For detection and localization of prostate cancer

Gallium 68 PSMA-11 - For detection and localization of prostate cancer Drug Approval Package: GALLIUM GA 68 PSMA-11 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GALLIUM GA 68 PSMA-11 Company: University of California Los Angeles Application Number: 212642 Approval Date: 12/01/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

11. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer T echnology appraisal guidance Published: 25 November 2020 www.nice.org.uk/guidance/ta660 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer Guideline 27-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer M.A. Haider, J. Brown, J. Chin, A. Loblaw, N. Perlis, N. Schieda, and the MPMRI in the Diagnosis of Clinically Significant Prostate Cancer Guideline Development Group (...) (Vancouver Style): Haider MA, Brown J, Chin J, Loblaw A, Perlis N, Schieda N. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer. Toronto (ON): Ontario Health (Cancer Care Ontario); 2021 February 11. Program in Evidence-Based Care Guideline No.: 27-2 Version 2, available on the OH (CCO) website. Copyright This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express

2021 Cancer Care Ontario

13. Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - Health economic evaluation

Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - Health economic evaluation Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy - NIPH NIPH's website uses cookies. Read more about our use of cookies in our privacy policy. Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Hydrogel rectal spacer SpaceOAR™ (...) in prostate cancer radiation therapy Subscribe me! You have subscribed to alerts about: Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy Health technology assessment Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy - Health economic evaluation Published 10.02.2021 We were commissioned to perform a health technology assessment of SpaceOAR™ hydrogel for prevention of radiation-induced side effects following treatment for prostate cancer. We were commissioned

2021 Norwegian Institute of Public Health

14. Abiraterone Accord - metastatic prostate cancer

Abiraterone Accord - metastatic prostate cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/163793/2021 EMEA/H/C/005408 Abiraterone Accord (abiraterone acetate) An overview (...) of Abiraterone Accord and why it is authorised in the EU What is Abiraterone Accord and what is it used for? Abiraterone Accord is a cancer medicine used to treat men with metastatic prostate cancer. This is cancer that affects the prostate gland (a gland of the male reproductive system). It is used when the cancer has spread to other parts of the body (metastatic). Abiraterone Accord is used together with prednisone or prednisolone (anti-inflammatory medicines): • when the cancer is newly diagnosed, high

2021 European Medicines Agency - EPARs

15. Axumin for functional imaging of prostate cancer recurrence

Axumin for functional imaging of prostate cancer recurrence Axumin for functional imaging of prostate cancer Axumin for functional imaging of prostate cancer recurrence recurrence Medtech innovation briefing Published: 8 February 2019 nice.org.uk/guidance/mib172 pathways Summary Summary The technology technology described in this briefing is Axumin, a radiopharmaceutical agent. It is intended for use in positron emission tomography (PET) to detect suspected prostate cancer recurrence in people (...) who have elevated prostate-specific antigen levels after primary curative treatment. It is currently the only licensed PET tracer indicated for use in recurrent prostate cancer. The inno innovativ vative aspects e aspects are that it is a prostate cancer-specific PET tracer with a novel mechanism of action based on amino acid transport. Its longer half-life and shorter uptake period may allow use in more people with suspected prostate cancer recurrence compared with other PET tracers. The intended

2019 National Institute for Health and Clinical Excellence - Advice

16. Enzalutamide for hormone-relapsed non-metastatic prostate cancer

Enzalutamide for hormone-relapsed non-metastatic prostate cancer Enzalutamide for hormone-relapsed non- Enzalutamide for hormone-relapsed non- metastatic prostate cancer metastatic prostate cancer T echnology appraisal guidance Published: 15 May 2019 www.nice.org.uk/guidance/ta580 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

17. Prostate cancer screening with the PSA test

Prostate cancer screening with the PSA test 1 Translation of Chapters 1 to 6 of the final report S19-01 Prostatakrebsscreening mittels PSA-Test (Version 1.0; Status: 24 April 2020 [German original], 10 June 2020 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission (...) No. S19-01 Prostate cancer screening with a PSA test 1 Extract of final report S19-01 Version 1.0 PSA screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Prostate cancer screening with a PSA test Commissioning agency: Federal Joint Committee Commission awarded on: 18 April 2019 Internal Commission No.: S19-01 Address of publisher: Institut für Qualität und Wirtschaftlichkeit

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC)

Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC) Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) - Repository of AIHTA GmbH English | Browse - - - Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) Grössmann, N. (2020): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Oncology Fact Sheet Nr. 23. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z

2021 Austrian Institute of Health Technology Assessment

19. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) CUAJ • February 2021 • Volume 15, Issue 2 © 2021 Canadian Urological Association CUA-CUOG GUIDELINE E81 Cite as: Saad F , Aprikian A, Finelli A, et al. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2021;15(2):E81-9. http://dx.doi.org (...) modified Oxford Center for Evidence-Based Medicine grading system. Based on a modified GRADE methodology, the strength of each recommendation is represented by the words STRONG or WEAK. Introduction Castration-resistant prostate cancer (CRPC) is defined by dis - ease progression despite castrate levels of testosterone and may present as either a continuous rise in serum prostate- specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases. Advanced

2021 Canadian Urological Association

20. Radical prostatectomy versus deferred treatment for localised prostate cancer. (Abstract)

Radical prostatectomy versus deferred treatment for localised prostate cancer. Prostate cancer is a common cancer but is oftentimes slow growing. When confined to the prostate, radical prostatectomy (RP), which involves removal of the prostate, offers potential cure that may come at the price of adverse events. Deferred treatment, involving observation and palliative treatment only (watchful waiting (WW)) or close monitoring and delayed local treatment with curative intent as needed (...) , AUA, and ASCO) until 3 March 2020.We included all randomised controlled trials (RCTs) that compared RP versus deferred treatment in patients with localised prostate cancer, defined as T1-2, N0, M0 prostate cancer.Two review authors independently assessed the eligibility of references and extracted data from included studies. The primary outcome was time to death from any cause; secondary outcomes were: time to death from prostate cancer; time to disease progression; time to metastatic disease

2020 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>